Agios Heads Toward Pivotal Study As FDA Places Hold On Backup
Biotech’s decision on which candidate to advance to pivotal studies in pyruvate-kinase R deficiency is clarified as backup candidate AG-519 is placed on clinical hold and shelved. Agios hopes to bring the first disease-modifying PKD drug therapy to market.
You may also be interested in...
Celgene Corp. will pursue accelerated approval later this year for AG-221 (enasidenib), the lead drug candidate under its partnership with Agios Pharmaceuticals Inc., which may separately seek accelerated approval for its wholly-owned drug AG-120 in 2017, giving Agios's precision medicines a foothold in the oncology market while the collaborators work to expand the labeling for their drugs.
Agios brings in a $78 million in financing from both previous venture investors and new public investor funds, as it embarks on research of rare diseases caused by an inborn error of metabolism.
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.